NCT06586255View on ClinicalTrials.gov

Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 29, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Urothelial Carcinoma BladderBladder Cancer
Interventions
RADIATION

Concurrent Immunotherapy and Radiation Therapy

Radiation therapy will begin between 12 to 18 weeks from the start of adjuvant nivolumab. Patients will receive radiation therapy for about 6 weeks.

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER